Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects — APOLLOE4-LTE  

Early Alzheimer's Disease Clinical Trial

Official title: Long-term Extension of a Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype

Status Not yet recruiting

Clinical Trial Summary

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.

Clinical Trial Description

This is a long-term extension study of the Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and imaging biomarker effects of ALZ-801 in subjects with Early Alzheimer's Disease and APOE4/4 genotype. Subjects who at initial screening for the Phase 3 study were 50-80 years old, had a clinical diagnosis of AD, carried the APOE4/4 genotype, and were at the early stage of disease (Early AD], who complete at least 78 weeks of the Phase 3 study while on study medication, are eligible for enrollment. Subjects will be treated for 52 weeks with ALZ-801, followed by a 4-week safety follow-up visit after the last dose of ALZ-801. Clinical trial sites, subjects and their study partner will remain blinded to the treatment (ALZ-801 or placebo) that they received in the core Phase 3 study. The primary efficacy outcome assessment is a measure of cognition (ADAS-Cog 13). Additional measures of global and functional impairments will also be assessed. Imaging and biomarkers of AD and neurodegeneration will be measured. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Early Alzheimer's Disease

• NCT number: NCT06304883
• Study type: Interventional
• Source: Alzheon Inc.
• Contact: Aidan Power, MB MRCPsych
• Phone: (860)-501-7837
• Email: aidan.power@alzheon.com
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: April 2024
• Completion date: January 2026